MTOR and Hypercholesterolemia: In a meta-analysis of patients with advanced malignancies treated with mTOR inhibitors (everolimus, temsirolimus, and ridaforolimus) the incidence rate of hypertriglyceridaemia was 35% (severe hypertriglyceridaemia 3%) and the incidence rate of hypercholesterolemia was 32% (severe hypercholesterolemia 3%) [74].